Eli Lilly is seeking approval to add its diabetes drug, Tirzepatide, to the US weight loss market after a successful clinical trial. Tirzepatide, taken once a week as an injection, led to an average weight loss of 15.7% in overweight or obese participants with type 2 diabetes. The drug mimics the gastrointestinal hormone GLP-1 and activates receptors in the brain involved in appetite regulation. The obesity treatments market could be worth $54bn by 2030, and Eli Lilly expects regulatory action on its submission as early as late 2023. Novo Nordisk has already marketed its weight loss drug, Wegovy, using a similar chemical.
Scientists achieved the groundbreaking detection of neutrinos generated within a particle collider, marking the first direct observation of collider-produced neutrinos. These elusive subatomic particles, known as “ghost particles,” typically traverse matter without interacting due to their negligible mass and lack of electric charge. The discovery was made possible using the FASERnu detector at the Large […]
In this study of 130 patients with classical papillary thyroid carcinoma (PTC), Next-Generation Sequencing (NGS) was utilized, revealing a high BRAF V600E mutation frequency (83.1%) attributed to Hokkaido’s high iodine intake from seaweed consumption. Unlike previous findings, direct correlation between BRAF V600E mutation and aggressive clinicopathologic features wasn’t established. However, co-existing mutations, notably with PIK3CA, […]
A recent study found that people with type 2 diabetes have changes in brain structure and function, as seen on MRI scans. These changes were more pronounced in people with longer duration of diabetes and diabetes complications. The study findings suggest that diabetes may have a negative impact on brain health, and early detection and […]